美托洛尔联合曲美他嗪治疗冠心病心力衰竭临床分析

目的：探讨冠心病心力衰竭采取美托洛尔联合曲美他嗪治疗临床效果，旨在为临床提供理论依据。方法方便选取该院2014年1月—2016年5月收治的120例冠心病心力衰竭患者，根据数字随机分为治疗组和对照组，各为60例，治疗组以美托洛尔联合曲美他嗪治疗，对照组常规对症治疗，比较两组治疗的临床效果及心功能改善情况。结果治疗组总有效率93.33%，对照组总有效率70.00%，两者总有效率比较差异有统计学意义(P﹤0.05)；治疗前，两组LVEF比较差异无统计学意义(P﹥0.05)；治疗后，治疗组LVEF(50.38±10.42)%与对照组(45.21±11.53)%比较，差异有统计学意义(P﹤0.05)。结论对于冠心病心力衰竭患者，临床上采取美托洛尔联合曲美他嗪治疗的临床疗效确切，优于常规对症治疗，能够显著改善患者心功能，值得临床推广。

Metoprolol Trimetazidine Coronary Heart Disease Clinical analysis

Objective Discussion Coronary Heart taking metoprolol trimetazidine clinical effect, aims to provide a theoreti-cal basis for clinical application. Methods Convenient selection our hospital in January 2014 — May 2016 were treated 120 cases of coronary heart disease patients with heart failure, according to figures randomly divided into treatment group and the control group, 60 patients treated with metoprolol trimetazidine treatment, control group of conventional symptomatic treatment, the clinical effects of treatment were compared and heart function improvement. Results Treatment group, the total efficiency of 93.33% in the control group, the total efficiency of 70.00%, the overall efficiency of the two had differ-ences(P<0.05); before treatment, the two groups showed no significant LVEF(P>0.05); after treatment, the treatment group LVEF (50.38±10.42)% and the control group (45.21 ± 11.53)% difference(P<0.05) was statistically significant. Conclusion For patients with coronary heart disease, to take on the clinical efficacy of metoprolol clinical trimetazidine exact treatment, superior to conventional symptomatic treatment, can significantly improve cardiac function, worthy of promotion.